Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BM4SIT

Financiado

Cerrado

AN INNOVATIVE CAUSAL THERAPY FOR ALLERGY SAFE AND RAPID INDUCTION OF AN ANTI IN...

AN INNOVATIVE CAUSAL THERAPY FOR ALLERGY SAFE AND RAPID INDUCTION OF AN ANTI INFLAMMATORY IMMUNE RESPONSE USING A MUTANT HYPOALLERGEN AND VITAMIN D3 Allergy is the most prevalent chronic inflammatory disease, having great socio-economic impact. Chronic lifelong dependency on symptomatic drugs is an expensive reality for the vast majority of allergy sufferers. Allergen-specific... ver más

31/01/2019

Academisch Medisch...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

Academisch Medisch Centrum AMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2019-01-31 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

Academisch Medisch Centrum A...

0.00€ | Lider

UNIVERSITY OF TURKU

N.D. | Participante

UHEI

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CNS2023-145619 Herramientas diagnósticas, pronósticas y terapéuticas 195K€ Cerrado

FAST TOWARDS SAFE AND EFFECTIVE IMMUNOTHERAPY OF PERSISTENT LIFE... 4M€ Cerrado

PID2020-113629RB-I00 PAPEL DE LIGANDOS DE ALERGENOS EN LA SENSIBILIZACION ALERGIC... 132K€ Cerrado

EVALUACIÓN DE LA EFICACIA DE LA INMUNOTERAPIA... EVALUACIÓN DE LA EFICACIA DE LA INMUNOTERAPIA SUBCUTÁNEA CON... 1M€ Cerrado

AIDA AIDA: Allergy Immunotherapy based on Designed Allergens 150K€ Cerrado

GAIT From symptom relief to disease modifying allergy treatment w... 71K€ Cerrado

Líder del proyecto

Academisch Medisch Centrum AMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Allergy is the most prevalent chronic inflammatory disease, having great socio-economic impact. Chronic lifelong dependency on symptomatic drugs is an expensive reality for the vast majority of allergy sufferers. Allergen-specific immunotherapy is the only causal and effective treatment targeting the underlying immune mechanism in a more cost-effective way. Yet, long treatment duration and risk of anaphylactic side-effects have prevented this treatment from becoming the first choice. BM4SIT aims at providing an escape from its current niche position by making the treatment safer, more effective and patient friendlier, i.e. developing a therapy with negligible side-effects but improved efficacy, achieved by less injections. The concept of BM4SIT is based on two innovations: replacing current natural allergen extracts by mutated recombinant allergens having been designed to be hypo-allergenic but hyper-immunogenic, and adding an adjuvant to support rapid and effective induction of an anti-inflammatory immune response. The allergen derivative chosen to bring this concept from bench to bedside is BM41, a mutant of the culprit allergen of birch pollen allergy, Bet v 1. Pre-clinical data have demonstrated strongly reduced allergenicity, significantly increased immunogenicity and efficacy in a mouse model for birch pollen allergy. The selected adjuvant is vitamin D3, which has been shown to promote active suppression of inflammation, both in vitro and in a mouse model. The product-focused, IP-protected consortium of BM4SIT will test the immunological and clinical added value of vitamin D3in combination with a current product in a randomized DBPC trial. First-in-man safety of BM41 will be evaluated against placebo, using a current product as comparator. Preliminary efficacy data will be obtained using surrogate in vitro serological and cellular tests.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores